Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | PDE9A | O76083 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2320138 | 1.00 | MKNK2 (0.47) | MKNK2PDE9ALRRK2ACACBPDE4D | |
| SCHEMBL30211008 | 1.00 | MKNK2 (0.47) | MKNK2PDE9ALRRK2ACACBPDE4D | |
| SCHEMBL5663343 | 0.91 | PDE9A (0.47) | MKNK2PDE9ALRRK2PDE4DPDE10A | |
| SCHEMBL6613792 | 0.80 | CDK4 (0.40) | MKNK2PDE9AACACBPDE10A | |
| SCHEMBL29576081 | 0.76 | EGFR (0.52) | IRAK4 | |
| SCHEMBL29586318 | 0.75 | PDE9A (0.40) | MKNK2PDE9AACACBPDE10A | |
| SCHEMBL29849730 | 0.75 | KDM4E (0.44) | MKNK2LRRK2 | |
| SCHEMBL22264349 | 0.75 | LRRK2 (0.40) | MKNK2LRRK2ACACBGRM5 | |
| SCHEMBL5463861 | 0.74 | HRH4 (0.51) | LRRK2PDE10A | |
| SCHEMBL21554467 | 0.74 | MKNK2 (0.67) | MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011092128-A1 | SUBSTITUTED NAPHTHYRIDINES AND THEIR USE AS SYK KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-04 | — | — | WO | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | MKNK2 246/4885PDE9A 4107/4885LRRK2 1083/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | MKNK2 200/4885PDE9A 3903/4885LRRK2 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.